In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y
- PMID: 36315955
- DOI: 10.7326/J22-0085
In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y
Abstract
Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 202;400:380-90. 35863366.
Comment on
-
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.Lancet. 2022 Jul 30;400(10349):380-390. doi: 10.1016/S0140-6736(22)00916-3. Epub 2022 Jul 18. Lancet. 2022. PMID: 35863366 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical